Ryan Allway May 17th, 2021 Psychedelics, Top News VANCOUVER, BC, May 17, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV“), has closed its previously-announced non-brokered private placement (the... Read more
Ryan Allway May 12th, 2021 Psychedelics, Top News Calgary, Alberta – TheNewswire – May 11, 2021. MedXtractor Corp. (CSE:MXT) (CNSX:MXT.CN) (“MedX” or the “Corporation”) updates its data record collection centre progress and its financial results for the year ended February 28, 2021. MedX reports that its data record collection centre has reached its practical capacity limit... Read more
Ryan Allway May 10th, 2021 Psychedelics, Uncategorized San Diego, California–(Newsfile Corp. – May 10, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO),... Read more
Nova Mentis Launches Autism Clinical Study
May 6, 2021
Ryan Allway May 6th, 2021 Psychedelics VANCOUVER, BC, May 6, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that its North American autism... Read more
Ryan Allway May 6th, 2021 Psychedelics VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its... Read more
Ryan Allway May 6th, 2021 Psychedelics NEW YORK, May 6, 2021 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health science focused biotechnology company utilizing psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the closing of a $27 million Series A round of funding led by Prime Movers Lab, an investor in breakthrough... Read more
Ryan Allway May 5th, 2021 Psychedelics VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“Akome”), as Chief Medical Officer... Read more
Ryan Allway May 4th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – May 4, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce that it has acquired, through its wholly owned subsidiary Eleusian Biosciences Corp. (“Eleusian“), the consumer goods product line, “Vitamind”, pursuant to... Read more
Ryan Allway May 4th, 2021 Psychedelics VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce... Read more
Havn Labs Jamaica Facility Now Fully Operational
May 4, 2021
Ryan Allway May 4th, 2021 Psychedelics The Company has started production of its first grow with local partner Hypha Wellness VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the... Read more
